News
Merck takes on Lilly/Nektar in IL-2 with $1.85bn Pandion buy
Merck & Co/MSD has agreed to buy Pandion for $1.85 billion, bolting on a pipeline of drugs for autoimmune and other immunological disorders headed by interleukin-2 (IL-2) based therapy
